MARKET

PGEN

PGEN

Precigen Inc
NASDAQ
1.120
+0.187
+20.03%
Pre Market: 1.130 +0.01 +0.89% 07:25 01/02 EST
OPEN
0.9300
PREV CLOSE
0.9331
HIGH
1.200
LOW
0.9000
VOLUME
39.98K
TURNOVER
0
52 WEEK HIGH
1.930
52 WEEK LOW
0.6513
MARKET CAP
328.01M
P/E (TTM)
-2.0442
1D
5D
1M
3M
1Y
5Y
1D
Precigen Completes Regulatory Filing For Approval Of Gene Therapy To Treat Respiratory Papillomatosis: Retail Sentiment Surges Amid Stock Rally
Barchart · 12/31/2024 02:54
Precigen Secures $79M Financing for 2025 Launch
TipRanks · 12/30/2024 21:48
Precigen Soars: Biologics License Application Submission For PRGN-2012 Targets First FDA-Approved Recurrent Respiratory Papillomatosis Treatment
Benzinga · 12/30/2024 17:31
Stifel thinks Precigen stock set to rebound after capital secured, BLA submitted
TipRanks · 12/30/2024 14:45
Precigen’s Strategic Advances and Financial Strength Boost Market Position for PRGN-2012
TipRanks · 12/30/2024 14:45
Precigen Announces Submission Of BLA For PRGN-2012 - Quick Facts
NASDAQ · 12/30/2024 12:37
Precigen Seeks FDA Priority Review for Gene Therapy Targeting Rare Respiratory Disease
Benzinga · 12/30/2024 12:08
Precigen submits BLA with request for priority review to FDA for PRGN-2012
TipRanks · 12/30/2024 12:05
More
About PGEN
Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Webull offers Precigen Inc stock information, including NASDAQ: PGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PGEN stock methods without spending real money on the virtual paper trading platform.